Clean air policy is usually argued in terms of respiratory disease, and the epidemiology has outgrown that framing. Air pollution is one of the largest environmental contributors to premature mortality worldwide, with fine particulate matter, ozone, nitrogen dioxide and traffic-related mixtures each carrying attributable risk. The organs it damages extend well beyond the lung. Evidence now links chronic exposure to pulmonary and extrapulmonary malignancies, neurodegenerative disorders, cardiovascular and renal disease, metabolic dysfunction-associated fatty liver disease, dermatological conditions and impairment of vision and hearing. Explaining that breadth requires two kinds of account running at once: why a given organ is vulnerable in the first place, and why so many organs fail together in the same person.
Organ-specific exposure biology answers the first question. Particle deposition, mucociliary clearance, local metabolic activation capacity and barrier architecture differ from tissue to tissue, so the same airborne mixture delivers very different internal doses to alveoli, to nasal epithelium, to skin and to the gut, which receives material cleared from the airways and swallowed. Shared molecular machinery answers the second. Oxidative stress generated by transition metals and organic components overwhelms antioxidant defences and damages membranes, proteins and DNA; inflammatory signalling follows, with the NLRP3 inflammasome and interleukin-1β acting as a recurring node across organs; epigenetic remodelling alters promoter methylation, histone marks and non-coding RNA profiles in ways that outlast the exposure itself; and extracellular vesicles carry proteins, lipids and microRNAs from exposed cells into the circulation, where they reprogramme distant tissues. This combination clarifies how a limited set of drivers generates markedly different disease phenotypes, and it explains why effects measured in one organ predict risk in another. Early-life windows appear to matter more than adult exposure, since lung growth and immune education are still under way when exposure begins.
For cancer, the conceptual shift matters more than any single finding. Direct mutagenesis by polycyclic aromatic hydrocarbons and related compounds remains real, but inflammation-driven tumour promotion is positioned as the dominant route in pollution-associated malignancy, and the same logic extends to tumours outside the thorax. A promoter does not need to damage DNA to accelerate a clone that already carries damage; it acts through microenvironmental signals that are measurable, modifiable and shared across tissues. Identification of discrete targets inside that axis, including the NLRP3/IL-1β pathway in pollution-associated tumour promotion, gives precision environmental medicine something specific to aim at rather than a diffuse injunction to avoid dirty air, and it suggests that the window for intervention may sit later than the moment of exposure. Initiators act at the instant of damage, whereas promoters act on clones that already exist, often decades afterwards, and that difference in timing decides whether prevention is still possible.
Susceptibility decides who pays for exposure, and the evidence treats genetic background as a decisive filter rather than a minor modifier. Quantitative trait locus mapping in mice, polygenic risk scores in human cohorts and candidate gene studies converge on variants affecting detoxification, antioxidant defence, immune regulation and host defence, with GSTT1, APOE ε4 and SFTPA among the recurring examples. Two gaps limit translation to the clinic. Real-world exposure is a chronic, low-dose mixture, whereas most toxicology relies on high-dose single agents, so synergy, cumulative effects and non-monotonic dose-response remain poorly characterised, and risk assessment built on one pollutant at a time understates the burden. Resilience is the mirror image of vulnerability and is barely studied, yet people who stay healthy under heavy exposure may hold protective mechanisms worth copying. Emission control remains the foundation of population protection; precision prevention, whether through anti-inflammatory agents, dietary antioxidant strategies or stratification by genotype, is the layer that decides how fast the remaining burden falls. Whether such interventions can be developed without diluting the priority given to emission control is the political question that follows the scientific one.
DOI
10.1007/s11684-026-1255-6